
Hematólogo. Linfomas y Leucemia Linfocítica Crónica. #LEx
Joined August 2018
- Tweets340
- Following96
- Followers339
- Likes3.5K
Nicolás Triantafilo C. retweeted
Bridging RT, but make it definitive.
CABI: ablative RT to every PET-avid site before axi-cel, mostly bulky.
Love the idea. Single center, early follow-up, frequent ICANS.
#ASH26 #lymsm #CARTcells
onlineprogram.hematology.org…
Nicolás Triantafilo C. retweeted
Does CD5+ LBCL present unique questions for CNS prophylaxis?
Reply in @JCO_ASCO with @mattwilson2287 & @Dr_KatLewis #lymsm
Reply to: Unanswered Question Regarding CNS Prophylaxis in CD5-Positive Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Nicolás Triantafilo C. retweeted
Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition | Bone Marrow Transplantation share.google/52fvK6i8woyEvnf…
Nicolás Triantafilo C. retweeted
Sepsis complicated 6.2% of CAR-T hospitalizations in the US (2017-2022) and changed everything: in-hospital mortality 28.7% vs 1.1% (aOR 33.96), plus more organ failure and thrombohemorrhagic events. Infection prevention is not optional. #mmsm doi.org/10.1016/j.jtct.2026.…
Nicolás Triantafilo C. retweeted
LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma
buff.ly/nJ1dh3x
Nicolás Triantafilo C. retweeted
Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategies | Blood Cancer Journal share.google/Q8BisVMoUfXiMaC…
Nicolás Triantafilo C. retweeted
Metabolic tumor volume trajectory during bridging and association with outcomes after CAR T infusion in large B-cell lymphoma | Bone Marrow Transplantation share.google/btBkQ427BuMJOnM…
Nicolás Triantafilo C. retweeted
Changes in muscle and fat distribution occur early in treatment highlighting the need for interventions to stabilize body composition. Patients with a higher volume of disease are more likely to experience certain side effects such as nerve pain. ow.ly/JWeb5104eB5
Nicolás Triantafilo C. retweeted
CAR-NK cells engineered to express IL-15 produced responses in 8 of 11 patients with refractory lymphoma or leukemia, including 7 complete responses. No cytokine release syndrome, neurotoxicity or graft-versus-host disease was observed.
doi.org/10.1056/NEJMoa191060…
this is why I love $IBRX and #anktiva
Nicolás Triantafilo C. retweeted
Incidence and risk factors for hypogammaglobulinemia after CD19 CAR T-cell therapy
ashpublications.org/bloodict…
Nicolás Triantafilo C. retweeted
CMV reactivation is common after CAR T-cell therapy for #LBCL, including in the 2L setting. Corticosteroid exposure is a major risk factor for CMV reactivation. Read in Blood ICT: ow.ly/tT205103NCK
Nicolás Triantafilo C. retweeted
New publication 📝 Results from a phase II trial, published in @BloodPortfolio, show that glofitamab + pola-R-CHP achieved a 95% CR rate in patients with newly diagnosed DLBCL or HGBCL.
Learn more about aggressive B-cell lymphomas: bit.ly/4aCi7Xu
#DLBCL #Lymphoma #lymsm #MedNews #MedEd
Nicolás Triantafilo C. retweeted
Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
aacrjournals.org/bloodcancer…
Nicolás Triantafilo C. retweeted
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study aacrjournals.org/bloodcancer…
Nicolás Triantafilo C. retweeted
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL.
In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵
ashpublications.org/bloodadv…
Nicolás Triantafilo C. retweeted
Frontline Bruton tyrosine kinase inhibitors are associated with improved response and PFS in primary CNS lymphoma
ashpublications.org/bloodadv…
Nicolás Triantafilo C. retweeted
Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma
nature.com/articles/s41408-0…
Nicolás Triantafilo C. retweeted
Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma
ashpublications.org/bloodadv…
Nicolás Triantafilo C. retweeted
Just published in @BloodAdvances!
"CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States"
Only ~15% of patients receive CAR T.
We need to continue generating data, raising awareness, and improving access and utilization.
ashpublications.org/bloodadv…
Thanks to all the authors and collaborators at @bmsnews
@lymphomaphilia @KrishPatelMD @LNastoupilMD @mana1981















